FDA Approved Drugs: Changes to Approved Drugs
Therapeutic Drug Monitoring: Affecting Factors
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Alzheimer's Disease: Treatment
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Feb 20, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Daniel M Hartung1, Nico Gabriel2, Walid F Gellad3
1Pharmacy Practice, Oregon State University.
Net prices for oral multiple sclerosis (MS) disease-modifying therapies (DMTs) increased less than list prices due to discounts. Monoclonal antibody (MAb) DMT net prices rose significantly, with discounts offsetting fewer price increases.
Area of Science:
Background: